Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update

Aditxt, Inc. (NASDAQ:ADTX) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 212,300 shares, a growth of 988.7% from the March 31st total of 19,500 shares. Approximately 10.8% of the company’s stock are sold short. Based on an average daily volume of 361,100 shares, the days-to-cover ratio is currently 0.6 days.

Aditxt Trading Up 6.8 %

NASDAQ ADTX traded up $0.16 during trading on Thursday, reaching $2.53. The company’s stock had a trading volume of 180,857 shares, compared to its average volume of 343,606. Aditxt has a twelve month low of $2.14 and a twelve month high of $68.08. The business’s fifty day moving average price is $3.25 and its 200-day moving average price is $4.59.

Hedge Funds Weigh In On Aditxt

A hedge fund recently bought a new stake in Aditxt stock. Armistice Capital LLC acquired a new position in Aditxt, Inc. (NASDAQ:ADTX) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 28,000 shares of the company’s stock, valued at approximately $350,000. Armistice Capital LLC owned 11.67% of Aditxt at the end of the most recent reporting period. Institutional investors and hedge funds own 15.54% of the company’s stock.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.